Abstract:The process of developing new drugs is widely acknowledged as being time-intensive and requiring substantial financial investment. Despite ongoing efforts to reduce time and expenses in drug development, ensuring medication safety remains an urgent problem. One of the major problems involved in drug development is hepatotoxicity, specifically known as drug-induced liver injury (DILI). The popularity of new drugs often poses a significant barrier during development and frequently leads to their recall after launch. In silico methods have many advantages compared with traditional in vivo and in vitro assays. To establish a more precise and reliable prediction model, it is necessary to utilize an extensive and high-quality database consisting of information on drug molecule properties and structural patterns. In addition, we should also carefully select appropriate molecular descriptors that can be used to accurately depict compound characteristics. The aim of this study was to conduct a comprehensive investigation into the prediction of DILI. First, we conducted a comparative analysis of the physicochemical properties of extensively well-prepared DILI-positive and DILI-negative compounds. Then, we used classic substructure dissection methods to identify structural pattern differences between these two different types of chemical molecules. These findings indicate that it is not feasible to establish property or substructure-based rules for distinguishing between DILI-positive and DILI-negative compounds. Finally, we developed quantitative classification models for predicting DILI using the naïve Bayes classifier (NBC) and recursive partitioning (RP) machine learning techniques. The optimal DILI prediction model was obtained using NBC, which combines 21 physicochemical properties, the VolSurf descriptors and the LCFP_10 fingerprint set. This model achieved a global accuracy (GA) of 0.855 and an area under the curve (AUC) of 0.704 for the training set, while the corresponding values were 0.619 and 0.674 for the test set, respectively. Moreover, indicative substructural fragments favorable or unfavorable for DILI were identified from the best naïve Bayesian classification model. These findings may help prioritize lead compounds in the early stage of drug development pipelines.

Differential expression of lymphocyte function-associated antigen 1 (LFA-1) on epidermotropic and non-epidermotropic T-cell clones.

The Liver Toxicity Knowledge Base (LKTB) and Drug-Induced Liver Injury (DILI) Classification for Assessment of Human Liver Injury

Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

A new prognostic model for drug-induced liver injury especially suitable for Chinese population

Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury

A Testing Strategy to Predict Risk for Drug-Induced Liver Injury in Humans Using High-Content Screen Assays and the ‘Rule-of-two’ Model

The application of cytokeratin-18 as a biomarker for drug-induced liver injury

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury

Prediction of Drug-Induced Liver Injury: From Molecular Physicochemical Properties and Scaffold Architectures to Machine Learning Approaches

Assessment of Emerging Biomarkers of Liver Injury in Human Subjects

Development of novel tools for the in vitro investigation of drug-induced liver injury

Improved Detection of Drug-Induced Liver Injury by Integrating Predicted in vivo and in vitro Data

Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions

Nonclinical Safety Signals in PharmaPendium Improve the Predictability of Human Drug-Induced Liver Injury

The liver toxicity biomarker study: phase I design and preliminary results.

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

MicroRNAs in Drug-induced Liver Injury.

Predose And Postdose Blood Gene Expression Profiles Identify The Individuals Susceptible To Acetaminophen-Induced Liver Injury In Rats

[An analysis on clinical characteristics and prognosis-related risk factors in patients with drug-induced liver injury].